GSTM1 and neoplasm: A further multivariate analysis demonstrated that lymph node status (P < .001), tumor size (P < .001), IHC‐based subtype (P < .001), chemotherapy or not (P < .001), and GSTM1‐null/present polymorphism (P = .02) were significant independent factors for RFS.